期刊
ADVANCED HEALTHCARE MATERIALS
卷 9, 期 21, 页码 -出版社
WILEY
DOI: 10.1002/adhm.202000650
关键词
bismuth; chemotherapy; hepatocellular carcinoma; radiotherapy; sorafenib
资金
- National Natural Science Foundation of China [21501121, 81472673, 81672720, 81672334, 81760497, 81970505, 81960446]
- Natural Science Foundation of Shanghai [19ZR1434700]
- Natural Science Foundation of Xizang [XZ2019ZRG-117]
- Shanghai Science and Technology Commission [16ZR1406100]
Sorafenib (SOR), a multi-kinase inhibitor for advanced hepatocellular carcinoma (HCC), reveals a limited therapeutic effect due to a lack of selectivity and evident drug resistance. In the present study, bismuth-based mesoporous nanomaterial (NBOF) is loaded with SOR and then coated with polyethylene glycol and folic acid conjugates (P-FA) to form an NBOF@SOR-P-FA nanocarrier system. The system achieves significantly enhanced anti-cancer efficacy by combining chemotherapy with radiotherapy. To evaluate the effect of synergistic treatment, cytotoxicity detection, Live/Dead staining, apoptotic assay, and Western blot analysis are performed. The results suggest that NBOF@SOR-P-FA significantly inhibits HCC cell proliferation and promotes cell apoptosis. Also, the NBOF@SOR-P-FA exhibits excellent biocompatibility by hemolysis and serum biochemical tests and produces a substantially enhanced contrast efficiency as compared to iohexol by computed tomography imaging. More importantly, the profound suppression of tumor growth and potentiation of apoptosis are observed in a mouse subcutaneous tumor model. Collectively, these results indicate that the bismuth-based nanotheranostic platform could enhance the therapeutic effect of sorafenib and serve as an innovative method for HCC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据